Author:
Mathew Krupa Ann,Indira Deepa,Joseph Jeena,Pillai Prakash Rajappan,Ramachandran Indu,Varadarajan Shankara Narayanan,Retnabai Santhoshkumar Thankayyan
Reference38 articles.
1. Suggitt M, Bibby MC (2005) 50 years of preclinical anticancer drug screening: empirical to target-driven approaches. Clin Cancer Res 11(3):971–981
2. Alley MC, Scudiero DA, Monks A, Hursey ML, Czerwinski MJ, Fine DL, Abbott BJ, Mayo JG, Shoemaker RH, Boyd MR (1988) Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. Cancer Res 48(3):589–601
3. Lovell JF, Billen LP, Bindner S, Shamas-Din A, Fradin C, Leber B, Andrews DW (2008) Membrane binding by tBid initiates an ordered series of events culminating in membrane permeabilization by Bax. Cell 135(6):1074–1084
4. Bates SE, Fojo AT, Weinstein JN, Myers TG, Alvarez M, Pauli KD, Chabner BA (1995) Molecular targets in the National Cancer Institute drug screen. J Cancer Res Clin Oncol 121(9–10):495–500
5. Tian H, Ip L, Luo H, Chang DC, Luo KQ (2007) A high throughput drug screen based on fluorescence resonance energy transfer (FRET) for anticancer activity of compounds from herbal medicine. Br J Pharmacol 150(3):321–334